Apollomics reports first half 2023 financial results and provides corporate update

Phase 2 data from vebreltinib (apl-101), a highly selective cmet inhibitor, in patients with nsclc with met exon14 skipping mutation expected second half 2023

APLM Ratings Summary

APLM Quant Ranking